Human FRAT2 Alexa Fluor® 350-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: FRAT2

FRAT2 (Frequently Rearranged in Advanced T-cell lymphomas-2; also GSK-3-binding protein FRAT2) is an intracellular member of the GSK-3-binding protein family. Although its predicted MW is 28 kDa, due to its highly acidic nature, it runs anomalously at 35 kDa in SDS-PAGE. It is widely expressed, and plays a key role in the regulation of the Wnt signaling pathway. Typically, in the absence of stimulation, GSK-3 beta and beta -catenin associate with Axin, where GSK-3 beta phosphorylates beta -catenin, leading to its turnover. Upon Wnt stimulation, GSK-3 beta phosphorylation of beta -catenin is decoupled, resulting in beta -catenin mediated gene activation. FRAT2 has the same effect as Wnt stimulation on GSK-3 beta activity, serving as a non-Wnt activator of beta -catenin. It does so by promoting the dissociation of GSK-3 beta from axin. It also interacts with Diversin, a participant in JNK signaling. This suggests that FRAT2 plays a role in both Wnt/ beta -catenin and PCP signaling pathways. Human FRAT2 is 233 amino acids (aa) in length. It contains an N-terminal acidic domain (aa 1-54), a Pro-rich segment (aa 60-107) and a GSK-3 beta binding region (aa 171-196). Over aa 31‑233, human FRAT2 shares 73% aa sequence identity with both mouse FRAT2 and human FRAT1.

Product Datasheets

Related Research Areas

• Cancer Biomarkers
• Wnt Signaling Modulators